Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Employees Not Required to Concur On Approvals - Union Agreement

Executive Summary

FDA employees are no longer required to indicate concurrence on an approval document with which they disagree under the new ratified contract of the National Treasury Employees Union FDA chapter.

You may also be interested in...

User Fee Revision Reduces Expected CDER Staffing Increases By 139 FTEs

A revision of FDA's estimated revenues from user fees will reduce the expected additions in staff to the Center for Drug Evaluation & Research to 40% of previous estimates.

FDA Suspension Of Drug Approval Needs To Be Easier, Task Force Suggests

FDA should seek a reduction in the "imminent hazard" standard for removing drug products from the market, FDA's Task Force on Risk Management suggests in its May 10 report to Commissioner Henney.

FDA To Assess Gaps Between Drug Review And Product Label Content

FDA will evaluate drug review documents and approved product labeling for gaps in information as part of a quality assurance effort for drug reviews in the Center for Drug Evaluation & Research.

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts